Chimerix (CMRX) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Chimerix (CHMX) PT Lifted to $50 at Brean Capital
May 11, 2015 12:37 PM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Chimerix (NASDAQ: CMRX) to $50.00 (from $45.00), saying Brinci has broad utility.
Aschoff commented, "The Phase 3 SUPPRESS trial with brincidofovir for the prevention of cytomegalovirus (CMV) in hematopoietic cell transplant patients is nearly 95% enrolled, and we expect it to be fully enrolled (n=450) in the summer of 2015 and read out pivotal... More
